Clinical trial · no report yet · Phase 3
MagnetisMM-6
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- NCT05623020 ↗
- Recruiting
- Pfizer
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| X threads | 8 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Daratumumab; Lenalidomide; Dexamethasone; Bortezomib
- Arms
- Part 1, Dose Level 1: Elranatamab + Daratumumab + Lenalidomide · Experimental
- Part 1, Multiple Dose Levels, Elranatamab + Daratumumab + Lenalidomide · Experimental
- Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide · Experimental
- Part 2 Randomized Arm B: Daratumumab + Bortezomib + Lenalidomide + Dexamethasone · Active comparator
- Part 1: Elranatamab + Lenalidomide · Experimental
- Enrollment
- 1,060 (estimated)
- Primary outcomes
- Part 1 Dose Limiting Toxicity
- Part 2: Progression free survival per IMWG
- Part 2: Minimal Residual Disease negative CR rate
- Sponsor
- Pfizer
- Start
- Nov 10, 2022
- Primary completion
- Oct 18, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05623020 · updated Sep 25, 2026